Burley’s big spod achieves >6% Li2O grades, flags ore sorting potential at Chubb
Metallurgy work shows low-grade lithium recoveries of 60%, while high-grade recoveries are 72% Both achieve >6% Li2O commercial concentrate grades Ore sorting tech shows potential [more…]
ASX Small Cap Lunch Wrap: Shares up in last trading sesh before Xmas (as usual), lithium winter 2.0 arrives
ASX 200 floating comfortably above 7510 points at lunchtime Lithium prices plumb fresh lows, putting pressure on producer Core (ASX:CXO) ASX small cap winners: Millennium [more…]
Resources Top 5: Aguia brings the Christmas gains with planned Andean takeover in South America
Aguia Resources leads ressie gains on the last day of trading before Christmas Tassie tungsten in the news, courtesy of Group 6 Metals KZR, LSR [more…]
Ground Breakers: The lithium price rut hits home as Core sinks on Finniss update
Core Lithium flags curtailment of mining operations and pauses work on underground expansion at Finniss project as lithium price drop bites, down 20%+ Spodumene concentrate [more…]
Dear Secret Broker: All I want for Christmas is a massive DONGA
After 35 years of stockbroking for some of the biggest houses and investors in Australia and the UK, the Secret Broker is regaling Stockhead readers [more…]
Christmas comes early for Besra with first gold concentrate produced at its flagship Bau project
Gold concentrate from Stage 1 bench-scale testing returned up to 47.28g/t gold Bulk samples were shipped to a third-party processing facility in the hope they [more…]
Azure spots more world-class assays from Andover discovery
Azure Minerals reports up to 1.33% Li2O from world-class Andover lithium discovery Earlier this week SQM and Hancock Prospecting joined forces to acquire the explorer [more…]
ASX Health Stocks: Next Science jumps almost 10pc after XPERIENCE study published in science journal
Next Science shares jump after publication of XPERIENCE on renowned journal Radiopharm to commence Phase 1 trial Clarity Pharma has commenced Phase 3 Next [more…]
Up to $1.8m funding from motor neurone disease foundation could be on the table for PharmAust
PharmAust invited to apply for up to $1.8m grant funding from FightMND Funding would be applied to company’s Phase 2 study of its drug to [more…]
Top 10 at 10: A couple of last-minute stocking stuffers … and one big lump of coal(ithium)
Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. [more…]